Farxiga (Dapagliflozin) Cost in Missouri: Prices, Insurance, and Savings in 2026

Farxiga is the brand name for dapagliflozin, an oral SGLT2 inhibitor manufactured by AstraZeneca and taken once daily as a 5 mg or 10 mg tablet. It is FDA-approved for type 2 diabetes, for reducing heart failure hospitalization risk in heart failure with reduced ejection fraction, and for slowing decline in chronic kidney disease, per the current FDA-approved prescribing information (label, accessdata.fda.gov). It is not the same drug as empagliflozin (Jardiance) or canagliflozin (Invokana), though all three are in the same drug class and are often treated interchangeably by insurers for glycemic indications.

The useful question for a Missouri patient is not "what does Farxiga cost" but "which coverage pathway applies to me," because Missouri Medicaid, commercial insurance, cash pay, and compounding each follow different rules, and those rules change what you pay far more than any single sticker price does.

The core answer and its boundary

Cash-pay list prices for brand SGLT2 inhibitors, including Farxiga, have run in roughly the $500 to $650 per month range in recent years, but the exact figure at any given Missouri pharmacy on any given day is volatile and not something this article can state precisely for 2026 without a live pharmacy quote. Missouri Medicaid (MO HealthNet) does not place Farxiga on its preferred formulary for type 2 diabetes alone, but heart failure and chronic kidney disease indications have a stronger evidentiary and guideline basis that supports a medical-necessity appeal. Commercially insured patients typically have the most cost-reduction options through formulary tiering and manufacturer copay assistance, while uninsured patients depend on patient assistance programs or compounded alternatives, each with real trade-offs. Readers should verify current pricing, formulary status, and program terms directly before making a decision, since none of these figures are fixed.

What is established, what is plausible, and what is not established

Established: Dapagliflozin's three FDA-approved indications (type 2 diabetes, HFrEF, CKD) are documented in the current FDA label. Dapagliflozin and empagliflozin are both approved for heart failure with reduced ejection fraction, and current cardiology guidance from the American College of Cardiology and American Heart Association has endorsed SGLT2 inhibitors as foundational heart failure therapy regardless of diabetes status (American Heart Association). Large randomized outcome trials (commonly referenced as DAPA-HF and DAPA-CKD) tested dapagliflozin in heart failure and chronic kidney disease populations and reported reduced risk of the trials' primary composite endpoints compared with placebo. The exact hazard ratios and confidence intervals from those trials are not restated here with specific numbers because this draft's citation list could not confirm the correct primary publication link; a reviewer should pull the New England Journal of Medicine DAPA-HF and DAPA-CKD papers directly before quoting effect sizes to patients or in appeals. Compounding of dapagliflozin by a licensed 503A pharmacy from bulk active ingredient, against an individual patient prescription, is permitted under the federal Drug Quality and Security Act framework (FDA, compounding laws and policies). Compounded drugs are not FDA-approved products and do not go through FDA's premarket review of safety, efficacy, and manufacturing quality.

Plausible but requiring current verification: That Missouri Medicaid will approve Farxiga through a documented medical exception for heart failure or CKD is consistent with how state Medicaid programs generally handle non-preferred agents with strong guideline support, but the specific prior authorization form, fax number, and turnaround time change periodically and must be confirmed with MO HealthNet's current preferred drug list and provider manual rather than assumed from a prior year's process.

Not established from the material available here: Any single dollar figure for Farxiga's 2026 Missouri cash price, exact commercial copay ranges by specific insurer, or the precise dollar cap and duration terms of AstraZeneca's savings card. These are the kind of numbers that shift with list price changes, formulary updates, and program renewals, and none of them should be treated as fixed facts on this page.

Does Missouri Medicaid cover Farxiga?

Missouri Medicaid has historically treated SGLT2 inhibitors as non-preferred for type 2 diabetes alone, favoring metformin, sulfonylureas, and select DPP-4 inhibitors on its preferred formulary. A request for Farxiga where diabetes is the only documented diagnosis is likely to be denied at the prior authorization stage unless the prescriber documents a specific clinical reason a preferred agent is inappropriate.

Heart failure and CKD diagnoses stand on firmer ground. Because major cardiology guidelines now recommend SGLT2 inhibitors for HFrEF independent of diabetes status, a prior authorization or appeal that documents a heart failure or CKD diagnosis, along with a trial of or contraindication to preferred alternatives, has a more defensible evidentiary basis. The exact MO HealthNet prior authorization form number, submission channel, and processing timeline should be confirmed with MO HealthNet directly at the time of filing, since administrative details of this kind change and a stale form or fax number will delay approval rather than speed it.

How Missouri commercial insurance plans typically handle Farxiga

Most commercial plans place brand-name Farxiga on a preferred-brand or non-preferred-brand tier rather than a generic tier, since no generic SGLT2 inhibitor was available in the United States as of the source material reviewed here. Tier placement, not the drug itself, drives most of the copay variation a patient will see: preferred-brand tiers generally carry a flat, moderate copay, while non-preferred tiers or coinsurance structures can leave a patient responsible for a much larger share of the negotiated price, especially before a deductible is met. High-deductible health plans expose patients to the full negotiated cash-equivalent price until the deductible is satisfied.

Prior authorization is common for SGLT2 inhibitors prescribed for type 2 diabetes, typically requiring documentation of a metformin trial or contraindication. Plans may relax that requirement when the prescription is for heart failure or CKD, given how strongly guideline bodies have endorsed the class for those indications. Because tier assignment and prior authorization criteria vary by plan and change at renewal, the only reliable way to know your specific cost is to check your plan's current formulary document or call member services.

The AstraZeneca savings card: what it does and where it does not help

AstraZeneca has offered a commercial copay savings card for Farxiga that reduces out-of-pocket cost for eligible commercially insured patients. As a category of program, manufacturer copay cards for brand SGLT2 inhibitors commonly work by covering some or all of the remaining copay after insurance processes the claim, up to a capped dollar amount per fill, and they are not available to patients enrolled in Medicare, Medicaid, Tricare, or VA benefits, since federal health care programs generally prohibit use of manufacturer copay assistance. The exact current cap, expiration terms, and enrollment mechanics for this specific card should be confirmed on AstraZeneca's own program materials or through the prescriber's office rather than assumed from a prior year, since manufacturer programs are renewed and modified on their own schedule.

One structural limitation is worth flagging regardless of the exact dollar terms: some health plans use copay accumulator or maximizer programs that prevent manufacturer copay assistance from counting toward a patient's deductible or annual out-of-pocket maximum. Whether a specific Missouri patient's plan does this is a plan-level detail, not a state law, and should be confirmed with the plan directly before relying on the card to make meaningful progress toward a deductible.

Compounded dapagliflozin in Missouri: legal but not equivalent

Licensed 503A compounding pharmacies in Missouri may legally compound dapagliflozin from bulk active pharmaceutical ingredient when they hold a valid, patient-specific prescription, under the federal Drug Quality and Security Act framework. This is meaningfully different from a 503B outsourcing facility, which may compound in bulk without patient-specific prescriptions under a separate regulatory pathway; a 503A pharmacy compounding without an individual prescription would be operating outside its authorized scope.

The core trade-off is straightforward: compounded dapagliflozin is not an FDA-approved product. It has not gone through the FDA's review of manufacturing consistency, purity, and bioequivalence that brand and generic approved drugs undergo. FDA's own guidance on compounding states plainly that compounded drugs are not FDA-approved and may or may not meet the same quality standards (FDA, compounding laws and policies). Cost savings relative to brand pricing can be real, but patients and prescribers should weigh that savings against the absence of FDA manufacturing oversight, and should confirm that any compounding pharmacy holds current Missouri Board of Pharmacy licensure and sources its active ingredient from an FDA-registered supplier before relying on it. Insurance, including Medicaid, generally does not reimburse compounded preparations, so this is an out-of-pocket path.

Telehealth prescribing in Missouri

Missouri permits telehealth establishment of a patient-prescriber relationship, and dapagliflozin is not a controlled substance, so an initial in-person visit is not a federal requirement for this particular drug. State-specific telehealth practice requirements do change periodically, so a prescriber's telehealth platform, not this article, is the right place to confirm current same-visit prescribing rules and any lab work (HbA1c, eGFR, serum potassium) it requires before or after starting therapy. Telehealth visit costs and whether a plan covers them at a standard copay both vary by platform and insurer and are not fixed facts that belong in a cost estimate here.

Comparing Farxiga with other SGLT2 inhibitors on cost

Jardiance (empagliflozin) and Invokana (canagliflozin) are the two other brand SGLT2 inhibitors commonly available in the United States, and their list prices have generally been in a similar range to Farxiga's, though exact current pricing for each should be checked independently rather than assumed to move together. Because no generic SGLT2 inhibitor has been broadly available, formulary preference, not clinical superiority, usually decides which one a given commercial or Medicaid plan prefers. For type 2 diabetes, ADA/ADA-style standards of care treat the class as largely interchangeable, so switching to whichever agent your plan prefers is a clinically reasonable way to reduce a copay, provided your prescriber confirms the correct dose and rechecks labs after the switch. For heart failure specifically, both dapagliflozin and empagliflozin carry FDA approval and strong guideline endorsement; a formulary-driven switch between the two for this indication is a reasonable cost-saving conversation to have with a cardiologist or prescriber, not a decision to make unilaterally.

Verification checklist: stable facts versus facts that expire

Use this to decide what you can trust as written today versus what you must re-check before acting on it.

Stable, unlikely to change quickly (verify once, trust for months to years):

• Dapagliflozin's FDA-approved indications (type 2 diabetes, HFrEF, CKD), confirm against the current FDA label.
• That dapagliflozin is not a controlled substance and belongs to the SGLT2 inhibitor class.
• That major cardiology guideline bodies recommend SGLT2 inhibitors for HFrEF independent of diabetes status.
• That 503A compounding of dapagliflozin from bulk API against an individual prescription is a federally recognized pathway, distinct from 503B bulk compounding.
• That federal law generally bars use of manufacturer copay cards by Medicare, Medicaid, Tricare, and VA beneficiaries.
• That Medicare Part D has a statutory annual out-of-pocket cap on covered drug spending as of 2025 under the Inflation Reduction Act.

Date-sensitive, must be re-verified before you rely on it (check every time, especially before a purchase or appeal):

• The current cash price of Farxiga at a specific Missouri pharmacy.
• Whether Missouri Medicaid's preferred drug list still excludes Farxiga for type 2 diabetes, and the current prior authorization form and submission channel.
• Your specific commercial plan's formulary tier, copay amount, and prior authorization criteria for the current plan year.
• The AstraZeneca savings card's current dollar cap, duration, and whether your plan applies a copay accumulator to it.
• Whether a given compounding pharmacy holds current Missouri Board of Pharmacy licensure and an FDA-registered API supplier.
• Whether your telehealth platform requires specific baseline labs before or after prescribing, and whether it manages prior authorization for you.

If a fact falls in the second column, do not act on a remembered number from a prior visit, a search result, or this article. Call the plan, the pharmacy, or MO HealthNet directly and get today's answer.